NYSEMKT: LCTX
Lineage Cell Therapeutics Inc Stock Ownership - Who owns Lineage Cell Therapeutics?

Insider buying vs selling

Have Lineage Cell Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Brian M. CulleyPresident and CEO2025-02-1112,547$0.65
$8.16kSell
George A. Samuel IiiGeneral Counsel2025-02-112,440$0.65
$1.59kSell
Broadwood Partners LPDirector2025-01-277,894,737$0.76
$6.00MBuy
Jill Ann HoweChief Financial Officer2024-11-2615,000$0.59
$8.85kBuy
George A. Samuel IiiGeneral Counsel2024-11-2615,000$0.60
$9.00kBuy
Michael H. MulroyDirector2024-11-2240,000$0.57
$22.64kBuy
Brian M. CulleyPresident and CEO2024-11-2140,000$0.60
$24.00kBuy
Jill Ann HoweChief Financial Officer2024-08-1610,500$0.89
$9.35kBuy

1 of 1

LCTX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when LCTX insiders and whales buy or sell their stock.

LCTX Shareholders

What type of owners hold Lineage Cell Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Broadwood Partners LP35.70%81,531,259$66.04MInsider
Broadwood Capital Inc21.70%49,560,992$40.14MInstitution
Neal C. Bradsher20.81%47,515,269$38.49MInsider
Blackrock Inc5.02%11,453,305$9.28MInstitution
Alfred D. Kingsley4.53%10,344,637$8.38MInsider
Vanguard Group Inc3.91%8,919,043$7.22MInstitution
Defender Capital LLC2.76%6,310,873$5.11MInstitution
Raffles Associates LP2.47%5,642,088$4.57MInstitution
George Karfunkel2.18%4,982,217$4.04MInsider
Geode Capital Management LLC1.96%4,485,586$3.63MInstitution

1 of 3

LCTX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LCTX41.73%58.27%Net Buying
CDXS46.22%53.78%Net BuyingNet Buying
LRMR52.63%47.37%
VYGR54.09%45.91%Net SellingNet Selling
VTYX40.90%59.10%Net BuyingNet Buying

Lineage Cell Therapeutics Stock Ownership FAQ

Who owns Lineage Cell Therapeutics?

Lineage Cell Therapeutics (NYSEMKT: LCTX) is owned by 47.89% institutional shareholders, 66.86% Lineage Cell Therapeutics insiders, and 0.00% retail investors. Broadwood Partners LP is the largest individual Lineage Cell Therapeutics shareholder, owning 81.53M shares representing 35.70% of the company. Broadwood Partners LP's Lineage Cell Therapeutics shares are currently valued at $66.04M.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.